Mono Pharmacare Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Mono Pharmacare Ltd is ₹ 11.65 as of 11 Jun 15:30 . The P/E Ratio of Mono Pharmacare Ltd changed from 32 on March 2024 to 13.2 on March 2025 . This represents a CAGR of -35.77% over 2 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Mono Pharmacare Ltd changed from ₹ 77.92 crore on March 2024 to ₹ 40.81 crore on March 2025 . This represents a CAGR of -27.63% over 2 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Mono Pharmacare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Morepen Laboratories Ltd for the Mar '26 is ₹ 493.18 crore as compare to the Dec '25 revenue of ₹ 487.97 crore. This represent the growth of 1.07% The ebitda of Mono Pharmacare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Mar '26 is ₹ 32.91 crore as compare to the Dec '25 ebitda of ₹ 50.12 crore. This represent the decline of -34.34% The net profit of Mono Pharmacare Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 15.7 crore over 8 quarters. This represents a CAGR of -34.12% The Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Mono Pharmacare Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Mono Pharmacare Ltd or Morepen Laboratories Ltd?

Market cap of Mono Pharmacare Ltd is 20 Cr while Market cap of Morepen Laboratories Ltd is 2,748 Cr

What are the key factors driving the stock performance of Mono Pharmacare Ltd and Morepen Laboratories Ltd?

The stock performance of Mono Pharmacare Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mono Pharmacare Ltd and Morepen Laboratories Ltd?

As of June 14, 2026, the Mono Pharmacare Ltd stock price is INR ₹11.65. On the other hand, Morepen Laboratories Ltd stock price is INR ₹50.16.

How do dividend payouts of Mono Pharmacare Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Mono Pharmacare Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.